Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment

Table 5 Effect of 3% hypertonic saline on brachial blood pressure, central blood pressure and pulse wave velocity in 23 healthy subjects treated with bendroflumethiazide or amiloride

Periods	Baseline	Infusion	Post infusion			PGLM RM
	0-90 min	150 min	180 min	210 min	240 min
bSBP
BFTZ	112 ± 9	118 ± 9d	116 ± 10	116 ± 11	117 ± 13	0.825
Amilorid	110 ± 8	115 ± 9d	114 ± 10d	114 ± 10b	114 ± 10b
Placebo	113 ± 10	117 ± 10d	115 ± 9	115 ± 8	115 ± 10
PGLM between subjects			0.679
bDBP
BFTZ	66 ± 7	63 ± 7b	62 ± 6d	62 ± 7d	62 ± 7b	0.055
Amilorid	64 ± 4	62 ± 5	60 ± 5b	61 ± 5	62 ± 6
Placebo	64 ± 6	63 ± 5	63 ± 5	62 ± 6	63 ± 6
PGLM between subjects			0.695
Pulse Rate
BFTZ	58 ± 10	61 ± 11a	61 ± 11b	62 ± 10b	62 ± 10b	0.782
Amilorid	57 ± 10	61 ± 11d	60 ± 10d	61 ± 11d	61 ± 11d
Placebo	55 ± 10	59 ± 12a	59 ± 12b	59 ± 12b	59 ± 13a
PGLM between subjects			0.712
cSBP
BFTZ	99 ± 7	98 ± 7				NS
Amilorid	96 ± 5	97 ± 7				NS
Placebo	98 ± 6	98 ± 8				NS
PANOVA	NS	NS
cDBP
BFTZ	67 ± 5	63 ± 6				< 0.001
Amilorid	65 ± 5	65 ± 6				NS
Placebo	65 ± 5	64 ± 5				NS
PANOVA	NS	NS
PWV
BFTZ	5.5 ± 0.6	5.3 ± 0.4				0.055
Amilorid	5.3 ± 0.5	5.3 ± 0.5				NS
Placebo	5.3 ± 0.7	5.3 ± 0.6				NS
PANOVA	NS	NS
AI
BFTZ	-2.2 ± 14.6	-5.9 ±17.7				NS
Amilorid	0.4 ± 12.5	-1.4 ± 13.4				NS
Placebo	-1.6 ± 14.6	-4.9 ± 18.6				0.034
PANOVA	NS	NS

Values are mean ± SD. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subjects factor for brachial systolic (bSBP), brachial diastolic blood pressure (bDBP) and pulse rate. Bonferroni correction was used for multiple comparisons between study-periods vs baseline.

^aP < 0.05;

^bP < 0.001;

^dP < 0.001; Paired t-test was used for comparison between post infusion vs baseline for central systolic (cSBP), central diastolic (cDBP), pulse wave velocity (PWV) and augmentation index (AIx).